D
Diederick E. Grobbee
Researcher at Utrecht University
Publications - 1108
Citations - 136069
Diederick E. Grobbee is an academic researcher from Utrecht University. The author has contributed to research in topics: Population & Risk factor. The author has an hindex of 155, co-authored 1051 publications receiving 122748 citations. Previous affiliations of Diederick E. Grobbee include National Heart Foundation of Australia & Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Change in blood pressure in offspring of parents with high or low blood pressure: the Dutch Hypertension and Offspring Study.
TL;DR: The findings suggest that the magnitude of familial aggregation of blood pressure increases during childhood and adolescence.
Journal ArticleDOI
595Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Journal ArticleDOI
Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015 : A systematic review and meta-analysis
Min Zhao,Kerstin Klipstein-Grobusch,Kerstin Klipstein-Grobusch,Xin Wang,Johannes B. Reitsma,Dong Zhao,Diederick E. Grobbee,Ian D. Graham,Ilonca Vaartjes +8 more
TL;DR: Cardiovascular medication use after MI is far from optimal in Chinese patients, even though the prevalence of use increased over the period 1995–2015, and a comprehensive strategy on secondary prevention is warranted.
Journal ArticleDOI
Neuropsychology of academic and behavioural limitations in school-age survivors of bacterial meningitis
Irene Koomen,A. Marceline van Furth,Miriam A C Kraak,Diederick E. Grobbee,J. J. Roord,Aag Jennekens-Schinkel +5 more
TL;DR: Children with limitations performed generically poorly on measures of cognitive functioning, speed, and motor steadiness, rather than having impairments in specific neuropsychological domains, which may explain the relatively poor speed and motor Steadiness of the group with limitations.
Journal ArticleDOI
A novel approach for establishing cardiovascular drug efficacy
TL;DR: This work states that drug development for cardiovascular and/ or renal diseases is currently often based on the modification of a single risk factor, such as blood pressure or lipid profiles, with the expectation that this will decrease the long-term risk of morbidity or mortality, and that the risk factor serves as a surrogate for the intended effect.